Figure S1 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

Authors:
  • CKChrisann Kyi
    Chrisann Kyi
  • VRVladimir Roudko
    Vladimir Roudko
  • RSRachel Sabado
    Rachel Sabado
  • YSYvonne Saenger
    Yvonne Saenger
  • WLWilliam Loging
    William Loging
  • JMJohn Mandeli
    John Mandeli
  • TTTin Htwe Thin
    Tin Htwe Thin
  • DLDeborah Lehrer
    Deborah Lehrer
  • MDMichael Donovan
    Michael Donovan
  • MPMarshall Posner
    Marshall Posner
  • KMKrzysztof Misiukiewicz
    Krzysztof Misiukiewicz
  • BGBenjamin Greenbaum
    Benjamin Greenbaum

Abstract
Supplemental Figure 1. Enrichments of Broad collection of immunological gene signatures in PBMC of SD (patient 002) and PD patients (patients 004 and 008). (A) non-supervised hierarchical clustering of selected gene signatures (FDR < 0,25). Gene names of enriched genesets are publicly available online at MSigDB: http://software.broadinstitute.org/gsea/msigdb/index.jsp. (B) Comparison of genesets enrichment scores between SD and PD patients. Positive values indicate enrichment in SD patient, while negative values - enrichment in PD patients. Enrichments were calculated based on outputs of GSEA analysis. X-axis: [Signal(SD) - Signal(PD)] / Signal(SD), where Signal is enrichment signal strength of geneset in patient 002 with SD response. Y-axis: [NES(SD) - NES(PD)] / NES(SD), where NES(SD) is normalized enrichment score of geneset in patient 002.